What "FDA-Approved" Means in a GLP-1 Telehealth Ad (And What It Doesn't)
"FDA-approved semaglutide delivered to your door." "Get FDA-approved GLP-1 medication through our licensed telehealth platform." "We prescribe only FDA-approved ingredients." Each of these phrases appears in current GLP-1 telehealth advertising. Each means something different. Two of them are potentially misleading. Here is what the phrase actually covers, and how to read advertising copy critically.
The precise meanings
"FDA-approved" is not a vague positive adjective. It refers to a specific regulatory status under the Federal Food, Drug, and Cosmetic Act. A drug is FDA-approved if it has completed the New Drug Application process and received an FDA approval letter for specific indications, doses, and formulations.
Only a handful of GLP-1-related products are FDA-approved for weight management or Type 2 diabetes in the United States:
- Wegovy (semaglutide, injectable) — Novo Nordisk — approved for chronic weight management
- Ozempic (semaglutide, injectable) — Novo Nordisk — approved for Type 2 diabetes
- Rybelsus (semaglutide, oral tablet) — Novo Nordisk — approved for Type 2 diabetes
- Zepbound (tirzepatide, injectable) — Eli Lilly — approved for chronic weight management
- Mounjaro (tirzepatide, injectable) — Eli Lilly — approved for Type 2 diabetes
- Saxenda (liraglutide, injectable) — Novo Nordisk — approved for weight management
- Victoza (liraglutide, injectable) — Novo Nordisk — approved for Type 2 diabetes
These products, manufactured in these exact formulations by these manufacturers, are FDA-approved. Nothing else is.
What compounded semaglutide and tirzepatide are (and aren't)
Compounded semaglutide and tirzepatide are not FDA-approved. They are compounded drug preparations produced by 503A pharmacies, operating under specific legal allowances that permit compounding when a drug is on FDA's shortage list or when a licensed prescriber determines a specific patient needs a customized formulation.
This doesn't mean they're illegal. It doesn't mean they're unsafe when properly compounded by a legitimate pharmacy. It means they are a different regulatory category. The Federal Food, Drug, and Cosmetic Act provides the compounding framework; FDA's New Drug Approval process does not apply to compounded preparations.
FDA has been explicit about this distinction. Their own communications refer to compounded semaglutide and tirzepatide as not FDA-approved. They have issued public alerts about adverse events associated with compounded GLP-1s and cautioned patients and providers about quality variations.
The three ways "FDA-approved" gets misused in ads
Misuse 1: Applying it to compounded product
The most direct misuse is calling compounded semaglutide or tirzepatide "FDA-approved" outright. This is clearly inaccurate. It has been called out repeatedly by FDA and by state attorneys general in enforcement actions.
Misuse 2: Applying it to the active pharmaceutical ingredient
Some ads say things like "FDA-approved ingredient" or "made with FDA-approved semaglutide." This is deceptive even when the literal words aren't technically wrong. The implication is that the finished product is FDA-approved, when in fact only the raw material (API) may meet certain FDA quality standards for bulk drug substances. The finished compounded preparation has no FDA approval.
Misuse 3: Applying it to the telehealth platform
"FDA-approved telehealth GLP-1 platform." FDA does not approve telehealth platforms. FDA approves drugs (and certain medical devices and biologics). Telehealth platforms are regulated by state medical boards, state pharmacy boards, DEA, and HIPAA. FDA is not in the platform approval business.
A telehealth platform can correctly say "we prescribe FDA-approved medications" if they only prescribe brand-name products. They cannot correctly say "we are FDA-approved."
The legitimate uses of the phrase
There are accurate ways to reference FDA approval in advertising:
- "We prescribe FDA-approved Wegovy and Zepbound" — correct, if the platform does so.
- "Our licensed providers may prescribe FDA-approved GLP-1 medications such as Ozempic or Mounjaro for appropriate patients" — correct and appropriately hedged.
- "We offer both FDA-approved brand-name GLP-1s and compounded alternatives, depending on your clinical situation" — correct, if the platform does both and is clear about which is which.
How to read a GLP-1 ad critically
- Find the exact phrase. Does the ad say "FDA-approved medication," "FDA-approved ingredients," or something vaguer? The noun matters.
- Check what product they actually prescribe. Dig into the FAQ or contact support. Brand-name only? Compounded? Both? The answer tells you whether the ad is accurate.
- Look for the word "compounded." A transparent compounded-product provider uses the word. A less transparent one does not.
- Cross-check FDA.gov. If you're unsure whether a specific product is FDA-approved, FDA's Orange Book is the authoritative list.
- Watch for deflection. If you ask "Do you prescribe FDA-approved medication?" and the answer is a deflection ("Our medications are made with pharmaceutical-grade ingredients..."), you have your answer.
Why this distinction matters
FDA approval is shorthand for an enormous amount of regulatory infrastructure: preclinical testing, pivotal trials with thousands of participants, manufacturing quality systems audits, labeling review, post-market safety monitoring, adverse event reporting requirements. When a product is FDA-approved, a lot of machinery is working to keep it safe, effective, and consistent.
Compounded products don't have that machinery. A reputable 503A compounding pharmacy has its own quality systems and state regulation, which can be robust, but they are categorically different from the FDA approval pathway.
For patients, this means two things:
- The safety record of FDA-approved products is extensively documented. The safety record of compounded GLP-1s is less well-characterized, and FDA has reported adverse events linked to compounded preparations, including dosing errors related to concentration differences.
- If something goes wrong with an FDA-approved product, the manufacturer has deep legal responsibility and resources. With a compounded product, responsibility is more distributed across the pharmacy, the platform, and the prescriber.
The enforcement landscape
FTC and state attorneys general have taken action against telehealth companies for deceptive "FDA-approved" claims on compounded products. Several consent decrees and settlements in recent years have established that this language is false advertising when applied to compounded GLP-1s. Expect more enforcement as the regulatory focus continues.
For consumers, the practical implication is that the phrasing of ads is starting to evolve. More providers are using accurate qualifiers ("compounded semaglutide," "not FDA-approved for weight loss," "custom-compounded to your prescription"). This is progress. The holdouts — the ones still saying "FDA-approved GLP-1" about compounded product — are the ones to be skeptical of.
The bottom line
"FDA-approved" has a precise meaning. In GLP-1 telehealth, it applies to seven specific brand-name products manufactured by two companies. Anything else — compounded semaglutide, compounded tirzepatide, oral semaglutide suspensions, sublingual tirzepatide — is not FDA-approved, regardless of how the ad is written. When in doubt, ask the provider directly: "Is the medication I'll receive FDA-approved, and if so, which brand name?" The answer you get determines whether the ad was accurate.